Probiotics could be used instead of antibiotics

13 April 2009

Using probiotics successfully against a number of animal diseases has helped scientists from University College Cork, Ireland, to understand  some of the ways in which they work, which could lead to them using  probiotics to treat human diseases.

"Rather than use commercially-available probiotics, we made our own  probiotic preparations containing safe bacteria such as Lactobacillus  species newly-isolated from human volunteers," said lead author Colin  Hill. "In all three animal diseases we observed a positive effect in  that the animals were significantly protected against infection."

Probiotics were also used to control disease in animals that were  already infected. The results of these tests proved that administering  these bacteria to an infected animal was as effective as the  best-available antibiotic therapies in eliminating the infectious agent  and resolving the symptoms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight